Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells

被引：2

作者：

Fiskus, Warren ^{[1
]}

Sharma, Sunil ^{[1
]}

Abhyankar, Sunil ^{[2
]}

McGuirk, Joseph ^{[2
]}

Bearss, David J. ^{[3
]}

Bhalla, Kapil

机构：

[1] Salarius Pharmaceut, Greenwood, IN USA

[2] Univ Kansas, Med Ctr, Div Hematol Oncol, Kansas City, KS 66103 USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.868.868

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

868

引用

页数：2

共 14 条

[1] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Fiskus, W.
Sharma, S.
Shah, B.
Portier, B. P.
Devaraj, S. G. T.
Liu, K.
Iyer, S. P.
Bearss, D.
Bhalla, K. N.
LEUKEMIA, 2014, 28 (11) : 2155 - 2164
[2] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W Fiskus
S Sharma
B Shah
B P Portier
S G T Devaraj
K Liu
S P Iyer
D Bearss
K N Bhalla
Leukemia, 2014, 28 : 2155 - 2164
[3] Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
W Fiskus
S Sharma
B Shah
B P Portier
S G T Devaraj
K Liu
S P Iyer
D Bearss
K N Bhalla
Leukemia, 2017, 31 : 1658 - 1658
[4] Pre-Clinical Efficacy of Combined Therapy with Novel β-Catenin Antagonist BC2059 and Histone Deacetylase Inhibitor Against Cultured and Primary AML Blast Progenitor Cells
Bhalla, Kapil
Fiskus, Warren
Horrigan, Stephen K.
Abhyankar, Sunil
McGuirk, Joseph
Sharma, Sunil
BLOOD, 2012, 120 (21)
[5] Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
W Fiskus
S Sharma
S Saha
B Shah
S G T Devaraj
B Sun
S Horrigan
C Leveque
Y Zu
S Iyer
K N Bhalla
Leukemia, 2015, 29 : 1267 - 1278
[6] Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W.
Sharma, S.
Saha, S.
Shah, B.
Devaraj, S. G. T.
Sun, B.
Horrigan, S.
Leveque, C.
Zu, Y.
Iyer, S.
Bhalla, K. N.
LEUKEMIA, 2015, 29 (06) : 1267 - 1278
[7] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells (vol 28, pg 2155, 2014)
Fiskus, W.
Sharma, S.
Shah, B.
Portier, B. P.
Devaraj, S. G. T.
Liu, K.
Iyer, S. P.
Bearss, D.
Bhalla, K. N.
LEUKEMIA, 2017, 31 (07) : 1658 - 1658
[8] Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
Fiskus, Warren
Mill, Christopher Peter
Karkhanis, Vrajesh
Lara, Bernardo H.
Bose, Prithviraj
Masarova, Lucia
Kadia, Tapan M.
Shao, Nancy
Bhalla, Isean
Maher, James V.
Khoury, Joseph D.
Sharma, Sunil
Manshouri, Taghi
Verstovsek, Srdan
Bhalla, Kapil N.
BLOOD, 2019, 134
[9] Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells
Fiskus, Warren
Wang, Yongchao
Jillella, Anand
Ustun, Celalettin
Johnston, Pace
Joshi, Rajeshree
Rao, Rekha
Ataja, Peter
Marquez, Victor
Bhalla, Kapil N.
BLOOD, 2008, 112 (11) : 1152 - 1152
[10] Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells
Fiskus, Warren
Mill, Christopher Peter
Soldi, Raffaella
Han, Roulan
Saenz, Dyana T.
Nowak, Agnieszka J.
Sun, Baohua
Saenz, David N.
DiNardo, Courtney D.
Borthakur, Gautam
Kadia, Tapan M.
Jin, Wendy
Ganesh, Thurika
Rao, Vaishnavi
Khoury, Joseph David
Sharma, Sunil
Bhalla, Kapil N.
BLOOD, 2018, 132

← 1 2 →